Proactiveinvestors recommends
Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:CIR
Latest Price: 0.43  (-2.27% Descending)
52-week High:0.65
52-week Low:0.43
Market Cap:19.95M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Circadian Technologies

Circadian Technologies (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.

 

Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply.

Pdf

Circadian Technologies: Dr Jonathan Skipper and Carlo Montagner to retire from board

Monday, October 03, 2011 by John Phillips
Circadian Technologies: Dr Jonathan Skipper and Carlo Montagner to retire from board

Circadian Technologies (ASX: CIR, OTCQX:CKDXY) has announced the retirement of two board members, with Dr Jonathan Skipper to retire as a director on the board in November, with Carlo Montagner to retire later this month.

Circadian chairman, Ms Dominique Fisher, said “On behalf of the board and the shareholders of Circadian, I thank both Jonathan and Carlo for their valuable contributions and commercial insights over the years.

"While it is disappointing to lose them as Directors we are glad that we will maintain their expertise through their ongoing roles with Circadian’s Product Development Review Committee.”

Circadian is currently in a very interesting phase, and just last week announced that the company had taken a significant step forward, filing a new drug application to the U.S. Food and Drug Administration (FDA) to start clinical studies for its VGX-100 antibody to treat cancer. 

An Investigational New Drug Application (IND) is a request for authorisation from the U.S. Food and Drug Administration (FDA) to administer an investigational drug to humans.

The first trial or Phase I will involve the treatment of a variety of different cancer types in patients with late stage cancer.

Circadian is focussed on developing VGX-100 (a human antibody against VEGF-C) as a treatment for solid tumours - including glioblastoma and colorectal cancer - as the first target indications for VGX-100.

VGX-100 works by blocking the growth of lymphatics. Circadian has already invested considerably in the VGX-100 molecule in terms of manufacturing, toxicology studies and other pre-clinical activities.

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.